Biome’s FY25 International Sales Jump 69% on New Deals in Ireland, NZ, Canada

International Sales Momentum

Biome Australia Limited (ASX, BIO) has marked a pivotal year in its international expansion efforts, reporting a 69% increase in international sales revenue for the fiscal year 2025, reaching approximately $1.5 million. This growth reflects the company’s successful strategy to broaden its global footprint beyond its domestic market, capitalizing on rising demand for its flagship Activated Probiotics range.

The company’s international sales surge is underpinned by a series of newly secured strategic distribution agreements across three key markets, Ireland, New Zealand, and Canada. These partnerships are expected to unlock access to thousands of additional pharmacy and health food retail locations starting in the first quarter of FY26, setting the stage for accelerated market penetration.

Strategic Distribution Partnerships

In Ireland, Biome has partnered with Uniphar, a major pharmaceutical wholesaler servicing over 1,400 pharmacies, facilitating a broad and immediate launch of Activated Probiotics into leading pharmacy chains. Meanwhile, in New Zealand, the company has aligned with Propharma, the country’s largest pharmacy wholesale network and a subsidiary of the EBOS Group, which also distributes Biome’s products in Australia.

Canada represents a particularly dynamic growth market for Biome, where initial demand has outpaced expectations. The company has secured multiple agreements with prominent pharmacy and health food retailers, including Pure Pharmacy Group in British Columbia and Healthy Planet Group nationally, as well as Nature’s Emporium and Nature’s Signature in Ontario. This rapid rollout is supported by the recruitment of dedicated sales and education personnel, with plans to introduce additional products pending Health Canada registration.

Building a Global Sales and Education Network

Biome’s international expansion is supported by a centralized Australian headquarters that provides consistent brand messaging, product knowledge, and operational support to satellite sales and education teams in each market. This approach ensures tailored engagement with local partners and health professionals, reinforcing Biome’s reputation as a scientifically backed provider of natural health products.

Managing Director Blair Vega Norfolk expressed confidence in the company’s trajectory, highlighting the successful execution of international business plans and the promising feedback from stakeholders across health professionals, distributors, retailers, and consumers. The upcoming launch of Activated Therapeutics is anticipated to further strengthen Biome’s position in these growth markets.

Outlook for FY26 and Beyond

With these foundational partnerships in place, Biome is strategically positioned for significant international growth in FY26. The company’s focus on expanding distribution channels and product offerings aligns with its mission to make innovative, evidence-based natural health solutions accessible worldwide. Investors and market watchers will be keen to observe how Biome leverages these new agreements to translate international momentum into sustained revenue growth.